Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer
A Cost-Effectiveness Analysis
Bibliographic Data
| ID | 22091030 |
|---|---|
| Authors | Peng-Fei Zhang (0009-0009-4972-6412, Sichuan University), Dan Xie (0000-0003-2242-3138, Sichuan University), Qiu Li (0000-0002-0864-4885, Sichuan University, corresponding author) |
| Year | 2021 |
| Volume | 9 |
| Pages | 608375-608375 |
| Publication date | 2021-02-09 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2021.608375 |
| PMID | 33634066 |
| OpenAlex | W3129146810 |
| Language | EN |
| Citations received | 3 |
| References cited | 30 |
Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives. Materials and Methods: A Markov model with three health states: progression-free survival (PFS), progressive disease (PD), and death, was constructed. All patients were assumed to enter the model in the PFS state and transit according to the transition structure. Efficacy data were derived from the ENZAMET trial and Weibull distribution curves were modeled to fit the survival curves. Costs in the model included cost of drugs, best-supportive care (BSC), follow-up, tests, and adverse events (AEs)-related treatments. The primary endpoint of the study was incremental cost-effectiveness ratio (ICER). In addition, the impact of several key parameters on the results of the cost-effectiveness analysis was tested with one-way sensitivity analyses and probabilistic sensitivity analyses. Results: Overall, ICERs were $430,933.95/QALY and $225,444.74/QALY of addition of enzalutamide to androgen deprivation therapy (ADT) vs. ADT from the US and Chinese payers' perspective, respectively. The most influential factors were the utility for the PFS state and the cost of enzalutamide. At the willingness-to-pay (WTP) thresholds of $100,000.00/QALY in the US and $28,988.40/QALY in China, the probability of adding enzalutamide to first-line treatment being a cost-effective option for mHSPC was 0%. Conclusions: Based on the data from the ENZAMET trial and the current price of enzalutamide, adding enzalutamide to first-line treatment is not cost-effective for patients with mHSPC from the US and Chinse payers' perspectives
Androgen deprivation therapy · Androgen receptor · Cancer · Cost effectiveness · Enzalutamide · Prostate cancer · Medicine · Prostate Cancer Treatment and Research · Radiopharmaceutical Chemistry and Applications · Statistical Methods in Clinical Trials · Internal Medicine · Oncology
Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer
Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China
| Unique citing works | 3 |
|---|---|
| Citations per year | 1 |
| Citation span | 2023 - 2026 (4) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 3 |